<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285660</url>
  </required_header>
  <id_info>
    <org_study_id>RD11/9711</org_study_id>
    <secondary_id>11/YH/0213</secondary_id>
    <nct_id>NCT02285660</nct_id>
  </id_info>
  <brief_title>Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume Definition</brief_title>
  <official_title>Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume Definition for Patients With Lung, Lower Oesophageal and Pancreatic Carcinomas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leeds Teaching Hospitals Charitable Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Leeds Teaching Hospitals NHS Trust</source>
  <brief_summary>
    <textblock>
      The aim of high dose radiotherapy treatment is to deliver enough radiation to the tumour to&#xD;
      kill all the cancer cells while at the same time giving a low dose of radiation to the normal&#xD;
      parts of the body to reduce the side effects of treatment. This requires the cancer&#xD;
      specialist to accurately identify the areas of cancer on a computed tomography (CT) scan.&#xD;
      Positron emission tomography computed tomography (PETCT) scans use radioactive sugar that is&#xD;
      injected into the patient. This sugar goes into cancer cells and shows up as a bright spot on&#xD;
      the PET scan, allowing the doctors to see tumours more accurately. Some cancers move with&#xD;
      breathing, for example lung, pancreas and oesophageal (or gullet) cancers. Fourdimensional CT&#xD;
      scanning (4DCT) is a special type of CT scan that allows the motion of the tumour to be seen&#xD;
      and measured accurately. This information can then be used to help ensure that the&#xD;
      radiotherapy correctly treats the moving tumour.&#xD;
&#xD;
      The aim of this study is to see if there are possible benefits to combining PET with 4DCT to&#xD;
      get a 4D PETCT scan for tumours that move with breathing. This study is divided into three&#xD;
      cancer types; lung, lower oesophagus and pancreatic cancer.&#xD;
&#xD;
      First the investigators are going to test the use of 4D PETCT in the radiotherapy planning of&#xD;
      these tumours to see if it helps the doctor to identify the cancer.&#xD;
&#xD;
      Secondly, the investigators are going to see if the 4D PETCT helps to show areas within the&#xD;
      cancer that are potentially more active. This might then allow us to target a higher dose to&#xD;
      these areas, which could potentially improve the chance of controlling and curing the cancer.&#xD;
      Patients' standard treatment will not be altered by participating in the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Whole body 4D PET-CT for improved Target Definition/Delineation (feasibility and benefit) (ability to identify the cancer and ability to show areas within the cancer that are potentially more active allowing target of higher dose to these areas)</measure>
    <time_frame>Up to two hours</time_frame>
    <description>To evaluate the feasibility and potential benefit of utilising 4D PET-CT for improved Target Definition/Delineation and to assess optimal segmentation of PET data</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Lung Carcinoma</condition>
  <condition>Lower Oesophageal Carcinoma</condition>
  <condition>Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Routine CT scan plus 4D PET-CT scan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine CT scan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>4D PET-CT Scan</intervention_name>
    <arm_group_label>Routine CT scan plus 4D PET-CT scan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>Routine CT scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  WHO Performance status 02 (Appendix A)&#xD;
&#xD;
          -  Histologically proven non small cell lung carcinoma, distal oesophageal carcinoma or&#xD;
             pancreatic adenocarcinoma&#xD;
&#xD;
          -  Clinical decision made to proceed with a course of radiotherapy of curative intent&#xD;
             with or without concurrent chemotherapy&#xD;
&#xD;
          -  Measurable primary tumour and/or locoregional metastatic lymph nodes on&#xD;
             preradiotherapy imaging&#xD;
&#xD;
          -  Able to provide fully informed written consent&#xD;
&#xD;
          -  Able to lie flat for 1 hour&#xD;
&#xD;
          -  Not be pregnant or breast feeding. Female patients of childbearing potential must&#xD;
             agree to use effective contraception, be surgically sterile, or be postmenopausal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to Fluorine18 fludeoxyglucose (FDG)&#xD;
&#xD;
          2. Hypersensitivity to iodinated contrast media&#xD;
&#xD;
          3. Poorly controlled diabetes&#xD;
&#xD;
          4. Acute renal failure or moderate renal impairment (estimated glomerular filtration rate&#xD;
             &lt; 30 mL/min)&#xD;
&#xD;
          5. Claustrophobia precluding imaging&#xD;
&#xD;
          6. Uncontrolled pain&#xD;
&#xD;
          7. Urinary incontinence&#xD;
&#xD;
          8. Female patients must not be pregnant and if of child bearing age using adequate&#xD;
             contraception&#xD;
&#xD;
          9. Breast feeding&#xD;
&#xD;
         10. Serious psychiatric comorbidity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Andrew Scarsbrook</last_name>
    <phone>01132068212</phone>
    <email>andrew.scarsbrook@leedsth.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Scarsbrook</last_name>
      <phone>01132068212</phone>
      <email>andrew.scarsbrook@leedsth.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2014</study_first_posted>
  <last_update_submitted>November 6, 2014</last_update_submitted>
  <last_update_submitted_qc>November 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

